פריוויג'ן

Land: Israel

Sprache: Hebräisch

Quelle: Ministry of Health

Wirkstoff:

IMMUNOGLOBULINS, NORMAL HUMAN

Verfügbar ab:

CSL BEHRING LTD., ISRAEL

ATC-Code:

J06BA02

Darreichungsform:

תמיסה לאינפוזיה

Zusammensetzung:

IMMUNOGLOBULINS, NORMAL HUMAN 100 G/L

Verabreichungsweg:

תוך-ורידי

Verschreibungstyp:

מרשם נדרש

Hergestellt von:

CSL BEHRING AG, SWITZERLAND

Therapiegruppe:

IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM.

Therapiebereich:

IMMUNOGLOBULINS, NORMAL HUMAN, FOR INTRAVASCULAR ADM.

Anwendungsgebiete:

1. Replacement therapy in- Primary immunodeficiency syndromes such as:- Congenital agammaglobulinaemia and hypogammaglobulinaemia- Common variable immunodeficiency- Severe combined immunodeficiency- Wiskott-Aldrich syndrome- Myeloma or chronic lymphocytic leukaemia with severe secondary hypogammaglobulinaemia and recurrent infections-Children with congenital AIDS and recurrent infections2. Immunomodulation- Immune thrombocytopenic purpura (ITP) in children or adults at high risk of bleeding or prior to surgical interventions to correct the platelet count-Guillain-Barr? syndrome- Kawasaki disease3. Allogeneic bone marrow transplantation

Berechtigungsdatum:

2016-06-30